Discovery of Highly Potent, Selective, and Brain-Penetrant Aminopyrazole Leucine-Rich Repeat Kinase 2 (LRRK2) Small Molecule Inhibitors-Reference-Cited by-同舟云学术

Discovery of Highly Potent, Selective, and Brain-Penetrant Aminopyrazole Leucine-Rich Repeat Kinase 2 (LRRK2) Small Molecule Inhibitors

Published:2014-01-15 Issue:3 Volume:57 Page:921-936
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Estrada Anthony A.¹²,Chan Bryan K.¹²,Baker-Glenn Charles¹²,Beresford Alan¹²,Burdick Daniel J.¹²,Chambers Mark¹²,Chen Huifen¹²,Dominguez Sara L.¹²,Dotson Jennafer¹²,Drummond Jason¹²,Flagella Michael¹²,Fuji Reina¹²,Gill Andrew¹²,Halladay Jason¹²,Harris Seth F.¹²,Heffron Timothy P.¹²,Kleinheinz Tracy¹²,Lee Donna W.¹²,Pichon Claire E. Le¹²,Liu Xingrong¹²,Lyssikatos Joseph P.¹²,Medhurst Andrew D.¹²,Moffat John G.¹²,Nash Kevin¹²,Scearce-Levie Kimberly¹²,Sheng Zejuan¹²,Shore Daniel G.¹²,Wong Susan¹²,Zhang Shuo¹²,Zhang Xiaolin¹²,Zhu Haitao¹²,Sweeney Zachary K.¹²

Affiliation:

1. Departments of †Discovery Chemistry, ‡Neurosciences, §Biochemical and Cellular Pharmacology, ∥Drug Metabolism and Pharmacokinetics, ⊥Safety Assessment, and #Structural Biology, Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States

2. Departments of ∇Chemistry, ○Biochemical and Cellular Pharmacology, and ◆Drug Metabolism and Pharmacokinetics, BioFocus, Chesterford Research Park, Saffron Walden, CB10 1XL, United Kingdom

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/jm401654j

Reference69 articles.

1. Parkinson's disease

2. Erratum in.Lancet 2009, 374, 684.

3. Motor fluctuations and dyskinesias in Parkinson's disease: Clinical manifestations

4. Levodopa, motor fluctuations and dyskinesia in Parkinson’s disease

5. Mutations in LRRK2 Cause Autosomal-Dominant Parkinsonism with Pleomorphic Pathology

Cited by 112 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. LRRK2 in Parkinson's disease: upstream regulation and therapeutic targeting;Trends in Molecular Medicine;2024-08

2. Leucine-rich repeat kinase 2 (LRRK2) inhibitors for Parkinson’s disease: a patent review of the literature to date;Expert Opinion on Therapeutic Patents;2024-07-19

3. A designed ankyrin-repeat protein that targets Parkinson’s disease-associated LRRK2;Journal of Biological Chemistry;2024-07

4. Concurrent Optimizations of Efficacy and Blood–Brain Barrier Permeability in New Macrocyclic LRRK2 Inhibitors for Potential Parkinson’s Disease Therapeutics;Journal of Medicinal Chemistry;2024-04-29

5. Catalyzing a Cure: Discovery and development of LRRK2 inhibitors for the treatment of Parkinson’s disease;Bioorganic Chemistry;2024-02